Your browser doesn't support javascript.
nCOVID-19 Pandemic: From Molecular Pathogenesis to Potential Investigational Therapeutics.
Kabir, Md Tanvir; Uddin, Md Sahab; Hossain, Md Farhad; Abdulhakim, Jawaher A; Alam, Md Asraful; Ashraf, Ghulam Md; Bungau, Simona G; Bin-Jumah, May N; Abdel-Daim, Mohamed M; Aleya, Lotfi.
  • Kabir MT; Department of Pharmacy, Brac University, Dhaka, Bangladesh.
  • Uddin MS; Department of Pharmacy, Southeast University, Dhaka, Bangladesh.
  • Hossain MF; Pharmakon Neuroscience Research Network, Dhaka, Bangladesh.
  • Abdulhakim JA; Pharmakon Neuroscience Research Network, Dhaka, Bangladesh.
  • Alam MA; Department of Physical Therapy, Graduate School of Inje University, Gimhae, South Korea.
  • Ashraf GM; Department of Medical Laboratory, Faculty of Applied Medical Sciences, Taibah University, Yanbu, Saudi Arabia.
  • Bungau SG; School of Chemical Engineering, Zhengzhou University, Zhengzhou, China.
  • Bin-Jumah MN; King Fahd Medical Research Center, King Abdulaziz University, Jeddah, Saudi Arabia.
  • Abdel-Daim MM; Department of Medical Laboratory Technology, Faculty of Applied Medical Sciences, King Abdulaziz University, Jeddah, Saudi Arabia.
  • Aleya L; Department of Pharmacy, Faculty of Medicine and Pharmacy, University of Oradea, Oradea, Romania.
Front Cell Dev Biol ; 8: 616, 2020.
Article in English | MEDLINE | ID: covidwho-686482
Semantic information from SemMedBD (by NLM)
1. Pharmaceutical Preparations TREATS Patients
Subject
Pharmaceutical Preparations
Predicate
TREATS
Object
Patients
2. Inhibitor PART_OF RNA-Directed RNA Polymerase
Subject
Inhibitor
Predicate
PART_OF
Object
RNA-Directed RNA Polymerase
3. Pharmaceutical Preparations TREATS Patients
Subject
Pharmaceutical Preparations
Predicate
TREATS
Object
Patients
4. Inhibitor PART_OF RNA-Directed RNA Polymerase
Subject
Inhibitor
Predicate
PART_OF
Object
RNA-Directed RNA Polymerase
ABSTRACT
In December 2019, a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-related epidemic was first observed in Wuhan, China. In 2020, owing to the highly infectious and deadly nature of the virus, this widespread novel coronavirus disease 2019 (nCOVID-19) became a worldwide pandemic. Studies have revealed that various environmental factors including temperature, humidity, and air pollution may also affect the transmission pattern of COVID-19. Unfortunately, still, there is no specific drug that has been validated in large-scale studies to treat patients with confirmed nCOVID-19. However, remdesivir, an inhibitor of RNA-dependent RNA polymerase (RdRp), has appeared as an auspicious antiviral drug. Currently, a large-scale study on remdesivir (i.e., 200 mg on first day, then 100 mg once/day) is ongoing to evaluate its clinical efficacy to treat nCOVID-19. Good antiviral activity against SARS-CoV-2 was not observed with the use of lopinavir/ritonavir (LPV/r). Nonetheless, the combination of umifenovir and LPV/r was found to have better antiviral activity. Furthermore, a combination of hydroxychloroquine (i.e., 200 mg 3 times/day) and azithromycin (i.e., 500 mg on first day, then 250 mg/day from day 2-5) also exhibited good activity. Currently, there are also ongoing studies to evaluate the efficacy of teicoplanin and monoclonal and polyclonal antibodies against SARS-CoV-2. Thus, in this article, we have analyzed the genetic diversity and molecular pathogenesis of nCOVID-19. We also present possible therapeutic options for nCOVID-19 patients.
Keywords

Full text: Available Collection: International databases Database: MEDLINE Type of study: Etiology study Language: English Journal: Front Cell Dev Biol Year: 2020 Document Type: Article Affiliation country: Fcell.2020.00616

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Type of study: Etiology study Language: English Journal: Front Cell Dev Biol Year: 2020 Document Type: Article Affiliation country: Fcell.2020.00616